What Are Chimeric Antigen Receptor (CAR) T-cells and What is Their Potential Target Site in Multiple Myeloma?
CAR T-cell structure CARs are typically composed of four regions: (1) an extracellular antigen-binding domain; (2) a hinge or spacer peptide; (3) a transmembrane domain that anchors the CAR to the cell membrane; and (4) one or more intracellular signalling domains...Myeloma News
Powered By:
- Sanofi’s Sarclisa Bags NICE Recommendation
- Daratumumab-Based Regimen May Be Superior for First-Line Multiple Myeloma Treatment
- Penn Researchers Discover Potential Cause of Immunotherapy-Related Neurotoxicity, Chart Path Forward
- Genmab Shares Drop On Legal Battle With J&J Over Cancer Drug
- U.S. Food and Drug Administration (FDA) Accepts for Priority Review Bristol Myers Squibb and bluebird bio Application for Anti-BCMA CAR T Cell Therapy Idecabtagene Vicleucel (Ide-cel, bb2121)
- As Myeloma Options Increase, So Do Challenges
- GSK Highlights Scientific Advances Across Its Growing Oncology Portfolio At ESMO Virtual Congress 2020
- SpringWorks Therapeutics Announces Clinical Collaboration with Janssen to Evaluate Nirogacestat in Combination with Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
- Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma
- Cellectar Reports Data on CLR 131 Phase 2 CLOVER-1 Study in Triple Class Refractory Multiple Myeloma Patients